205117-47-1

Basic information

• Product Name: Bifendate Impurity E
• Synonyms: Bifendate Impurity E;Bifendate Impurity 7;7,7'-dimethoxy-5'-(methoxycarbonyl)-[4,4'-bibenzo[d][1,3]dioxole]-5-carboxylic acid;Bicyclol Impurity D;Bifendate Impurity
• CAS NO: 205117-47-1
• Molecular Formula: C₁₉H₁₆O₁₀
• Molecular Weight: 404.32434
• Mol File: 205117-47-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Bifendate Impurity E(CAS DataBase Reference)
• NIST Chemistry Reference: Bifendate Impurity E(205117-47-1)
• EPA Substance Registry System: Bifendate Impurity E(205117-47-1)

Safety Data

• Hazardous Substances Data: 205117-47-1(Hazardous Substances Data)

Usage

Description

Bifendate Impurity E, also known as 7,7''-Dimethoxy-[4,4''-Bi-1,3-benzodioxole]-5,5''-dicarboxylic Acid Monomethyl Ester, is a synthetic intermediate of Schisandrin C and an impurity found in Bifendate (B382890). It is utilized in the pharmaceutical industry for the development of anti-HBV drugs, specifically targeting the treatment of chronic hepatitis B.

Uses

Used in Pharmaceutical Industry:
Bifendate Impurity E is used as a synthetic intermediate for the development of anti-HBV drugs, specifically for the treatment of chronic hepatitis B. Its role in the pharmaceutical industry is crucial, as it contributes to the creation of medications that combat hepatitis B virus and improve the health outcomes of patients suffering from this chronic condition.

Upstream product

• 67-56-1 methanol 
• 111897-21-3 dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylic acid 
• 111897-19-9 DDB 

Downstream Products

• 1350363-27-7 (Z)-5-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)-2-ethoxyphenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-28-8 (Z)-5-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)-2-methoxyphenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-29-9 (E)-5-(3-((2,4-dioxothiazolidin-5-ylidene)methyl)phenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-30-2 (Z)-5-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)-2,6-dimethoxyphenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-31-3 (E)-5-(2,4-dichloro-6-((2,4-dioxothiazolidin-5-ylidene)methyl)phenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-32-4 (Z)-5-(2-bromo-4-((2,4-dioxothiazolidin-5-ylidene)methyl)phenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-33-5 (Z)-5-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)-2-fluorophenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-34-6 (E)-5-(2,4-dibromo-6-((2,4-dioxothiazolidin-5-ylidene)methyl)phenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-35-7 (E)-5-(5-((2,4-dioxothiazolidin-5-ylidene)methyl)-2-methoxyphenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-36-8 (E)-5-(2-((2,4-dioxothiazolidin-5-ylidene)methyl)phenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-37-9 (Z)-5-(4-((2,4-dioxothiazolidin-5-ylidene)methyl)phenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-38-0 (E)-5-(4-chloro-2-((2,4-dioxothiazolidin-5-ylidene)methyl)phenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-25-5 5-(4-formylphenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate 
• 1350363-26-6 5-(4-chloro-2-formylphenyl) 5'-methyl 7,7'-dimethoxy-4,4'-bibenzo-[d][1,3]dioxole-5,5'-dicarboxylate 

Relevant articles and documents

Development of tacrine-bifendate conjugates with improved cholinesterase inhibitory and pro-cognitive efficacy and reduced hepatotoxicity

A novel series of tacrine-bifendate (THA-DDB) conjugates (7a-e) were synthesized and evaluated as potential anti-Alzheimer's agents. These compounds showed potent cholinesterase and self-induced β-amyloid (Aβ) aggregation inhibitory activities. A Lineweaver–Burk plot and molecular modeling study showed that these compounds can target both catalytic active site (CAS) and peripheral anionic site (PAS) of acetylcholinesterase (AChE). The cytotoxicity of the conjugate 7d against PC12 and HepG2 cells and hepatotoxicity against human hepatocyte cell line (HL-7702) were found to be considerably less compared to THA. Moreover, treatment with 7d did not exhibit significant hepatotoxicity in mice. Finally, in vivo studies confirmed that 7d significantly ameliorates the cognitive performances of scopolamine-treated ICR mice. Therefore, 7d has high potential for the treatment of Alzheimer's disease and warrants further investigation.

Synthesis and evaluation of substituted dibenzo[c,e]azepine-5-ones as P-glycoprotein-mediated multidrug resistance reversal agents

A series of substituted dibenzo[c,e]azepine-5-ones (7a-h) were synthesized and evaluated as P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) reversal agents. The most potent compound 7h could significantly and selectively enhance the chemo-sensit

Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors

Overexpression of P-glycoprotein (P-gp) is one of the major problems to successful cancer chemotherapy. To find novel effective P-gp inhibitors, a series of bifendate-chalcone hybrids were synthesized and evaluated. Among them, the most active compound 8g